Catalyst Event
Natera Inc (NTRA) · Other
From Akros U.S. Tech 100 Index (AUT100)
3/16/2026, 12:00:00 AM
Announced the publication of two peer-reviewed studies on March 16, 2026, highlighting the clinical utility of its Signatera test in anal and rectal cancers, showing positive results for predicting survival and recurrence.
Korean Translation
2026년 3월 16일, 항문암 및 직장암에서 Signatera 테스트의 임상적 유용성을 강조하는 두 건의 동료 심사 연구 발표. 생존 및 재발 예측에 긍정적인 결과를 보임.
Related Recent Events
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Next earnings release for Q1 2027 is scheduled for 2026-06-09, with analysts forecasting an EPS of $1.07 estimated.
6/9/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Q4 and Full-Year Fiscal Year 2026 financial results scheduled; expected to have a medium impact as annual results typically influence guidance and investor sentiment.
5/20/2026, 12:00:00 AM
Fair Isaac Corporation (FICO) · Other
FICO World 2026 is scheduled to take place from May 19-22, 2026.
5/19/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
GE Aerospace (GE) · Other
The 2026 Annual Shareholders Meeting to be held online on May 5, 2026, scheduled. Routine meetings typically result in minimal price movement.
5/5/2026, 12:00:00 AM